Johnson & Johnson Shares Outstanding 1986-2025 | JNJ

Johnson & Johnson shares outstanding history from 1986 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Johnson & Johnson shares outstanding for the quarter ending June 30, 2025 were 2.419B, a 0.12% decline year-over-year.
  • Johnson & Johnson 2024 shares outstanding were 2.429B, a 5.12% decline from 2023.
  • Johnson & Johnson 2023 shares outstanding were 2.56B, a 3.89% decline from 2022.
  • Johnson & Johnson 2022 shares outstanding were 2.664B, a 0.38% decline from 2021.
Johnson & Johnson Annual Shares Outstanding
(Millions of Shares)
2024 2,429
2023 2,560
2022 2,664
2021 2,674
2020 2,671
2019 2,684
2018 2,729
2017 2,745
2016 2,789
2015 2,813
2014 2,864
2013 2,877
2012 2,813
2011 2,775
2010 2,789
2009 2,789
2008 2,836
2007 2,911
2006 2,961
2005 3,003
2004 2,993
2003 3,008
2002 3,054
2001 3,099
2000 3,099
1999 3,100
1998 2,834
1997 2,741
1996 2,724
1995 2,584
1994 2,572
1993 2,572
1992 2,622
1991 5,331
1990 2,665
1989 2,664
1988 5,329
1987 3,069
1986 3,069
1985 2,926
Johnson & Johnson Quarterly Shares Outstanding
(Millions of Shares)
2025-06-30 2,419
2025-03-31 2,424
2024-12-31 2,429
2024-09-30 2,428
2024-06-30 2,422
2024-03-31 2,430
2023-12-31 2,560
2023-09-30 2,550
2023-06-30 2,626
2023-03-31 2,606
2022-12-31 2,664
2022-09-30 2,661
2022-06-30 2,668
2022-03-31 2,667
2021-12-31 2,674
2021-09-30 2,675
2021-06-30 2,672
2021-03-31 2,673
2020-12-31 2,671
2020-09-30 2,669
2020-06-30 2,666
2020-03-31 2,671
2019-12-31 2,684
2019-09-30 2,670
2019-06-30 2,692
2019-03-31 2,699
2018-12-31 2,729
2018-09-30 2,728
2018-06-30 2,721
2018-03-31 2,732
2017-12-31 2,745
2017-09-30 2,738
2017-06-30 2,742
2017-03-31 2,755
2016-12-31 2,789
2016-09-30 2,785
2016-06-30 2,794
2016-03-31 2,804
2015-12-31 2,813
2015-09-30 2,807
2015-06-30 2,812
2015-03-31 2,826
2014-12-31 2,864
2014-09-30 2,864
2014-06-30 2,874
2014-03-31 2,875
2013-12-31 2,877
2013-09-30 2,881
2013-06-30 2,893
2013-03-31 2,859
2012-12-31 2,813
2012-09-30 2,818
2012-06-30 2,798
2012-03-31 2,775
2011-12-31 2,775
2011-09-30 2,778
2011-06-30 2,781
2011-03-31 2,773
2010-12-31 2,789
2010-09-30 2,786
2010-06-30 2,796
2010-03-31 2,797
2009-12-31 2,789
2009-09-30 2,793
2009-06-30 2,782
2009-03-31 2,790
2008-12-31 2,836
2008-09-30 2,831
2008-06-30 2,845
2008-03-31 2,866
2007-12-31 2,911
2007-09-30 2,913
2007-06-30 2,923
2007-03-31 2,924
2006-12-31 2,961
2006-09-30 2,948
2006-06-30 2,974
2006-03-31 2,993
2005-12-31 3,003
2005-09-30 3,006
2005-06-30 3,025
2005-03-31 3,024
2004-12-31 2,993
2004-09-30 3,009
2004-06-30 3,005
2004-03-31 3,005
2003-12-31 3,008
2003-09-30 3,008
2003-06-30 3,016
2003-03-31 3,019
2002-12-31 3,054
2002-09-30 3,027
2002-06-30 3,069
2002-03-31 3,115
2001-12-31 3,099
2001-09-30 3,111
2001-06-30 3,111
2001-03-31 3,107
2000-12-31 2,838
2000-09-30 3,113
2000-06-30 3,095
2000-03-31 2,822
1999-12-31 2,845
1999-09-30 2,748
1999-06-30 2,750
1999-03-31 2,751
1998-12-31 2,767
1998-09-30 2,746
1998-06-30 2,716
1998-03-31 2,767
1997-12-31 2,800
1997-09-30 2,672
1997-06-30 2,713
1997-03-31 2,755
1996-12-31 2,712
1996-09-30 2,727
1996-06-30 2,728
1996-03-31 2,724
1995-12-31 2,590
1995-09-30 2,591
1995-06-30 2,582
1995-03-31 2,572
1994-12-31 2,570
1994-09-30 2,573
1994-06-30 2,574
1994-03-31 2,572
1993-12-31 2,572
1993-09-30 2,590
1993-06-30 2,620
1993-03-31 2,622
1992-12-31 2,621
1992-09-30 2,622
1992-06-30 2,622
1992-03-31 2,664
1991-12-31 5,331
1991-09-30 2,665
1991-06-30 2,665
1991-03-31 2,665
1990-12-31 2,665
1990-09-30 2,665
1990-06-30 2,665
1990-03-31 2,665
1989-12-31 2,664
1989-09-30 2,664
1989-06-30 2,665
1989-03-31 3,069
1988-12-31 5,329
1988-09-30 2,697
1988-06-30 2,737
1988-03-31 2,763
1987-12-31 3,069
1987-09-30 2,762
1987-06-30 2,763
1987-03-31 2,761
1986-12-31 3,069
1985-12-31 2,926
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $450.090B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12